Cannabis Stocks: Analysts' April Ratings and Price Targets

1 2 3 4 5 6 7 8 9
Cannabis Stocks: Analysts' April Ratings and Price Targets PART 1 OF 9

Cannabis Stocks: Analysts’ April Ratings and Price Targets

Analyst ratings

In recent weeks, we’ve seen some of the major cannabis stocks facing selling pressures, wiping off YTD (year-to-date) gains for most companies. Canopy Growth (WEED), one of the largest cannabis producers in terms of capacity, has fallen nearly 15% YTD. Let’s see how analysts’ ratings and price targets have changed over the last month.

Cannabis Stocks: Analysts&#8217; April Ratings and Price Targets

Interested in WEED? Don't miss the next report.

Receive e-mail alerts for new research on WEED

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Canopy Growth

As of April 12, 2018, the overall mean consensus rating for Canopy Growth is unchanged at 2.6 compared to March. The overall recommendation for the stock is a “hold,” with five analysts recommending a “buy” compared to four in March. For the next 12-month period, three analysts are recommending a “hold” for the stock, and one analyst is recommending a “sell.”

Price target

The consensus mean price target for Canopy Growth is $36.80 Canadian, which would mean a potential upside of 33.1% from the closing price of $27.70 Canadian on April 12, 2018. The median price target is even higher at $40 Canadian, resulting in a potential upside of 44%.

Series overview

In this series, we’ll be looking at the ratings and price target changes for some of the listed cannabis stocks since March. We’ll include Aphria (APHQF), Aurora Cannabis (ACB), MedReleaf (MEDFF), and more.


Please select a profession that best describes you: